MX2020002702A - Metodo de tratamiento. - Google Patents

Metodo de tratamiento.

Info

Publication number
MX2020002702A
MX2020002702A MX2020002702A MX2020002702A MX2020002702A MX 2020002702 A MX2020002702 A MX 2020002702A MX 2020002702 A MX2020002702 A MX 2020002702A MX 2020002702 A MX2020002702 A MX 2020002702A MX 2020002702 A MX2020002702 A MX 2020002702A
Authority
MX
Mexico
Prior art keywords
subject
lymphoma
treatment method
treating
relates
Prior art date
Application number
MX2020002702A
Other languages
English (en)
Inventor
Derek Nigel John Hart
Georgina Jane Clark
Edward Alan Abadir
Xinsheng Ju
Ziduo Li
Original Assignee
Kira Biotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017903726A external-priority patent/AU2017903726A0/en
Application filed by Kira Biotech Pty Ltd filed Critical Kira Biotech Pty Ltd
Publication of MX2020002702A publication Critical patent/MX2020002702A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a un método para tratar el linfoma en un sujeto y, más particularmente, para tratar el linfoma de Hodgkin (HL) y el linfoma no Hodgkin (NHL). El método comprende administrar al sujeto una cantidad efectiva de una proteína de unión a CD83. La invención se refiere, además, a métodos para diagnosticar y evaluar el linfoma en un sujeto.
MX2020002702A 2017-09-13 2018-09-12 Metodo de tratamiento. MX2020002702A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017903726A AU2017903726A0 (en) 2017-09-13 Treatment method
PCT/AU2018/050987 WO2019051541A1 (en) 2017-09-13 2018-09-12 Treatment method

Publications (1)

Publication Number Publication Date
MX2020002702A true MX2020002702A (es) 2020-10-05

Family

ID=65722240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002702A MX2020002702A (es) 2017-09-13 2018-09-12 Metodo de tratamiento.

Country Status (10)

Country Link
US (1) US20200277396A1 (es)
EP (1) EP3681536A4 (es)
JP (1) JP2020533384A (es)
KR (1) KR20200066613A (es)
CN (1) CN111565749A (es)
AU (2) AU2018333275A1 (es)
CA (1) CA3074379A1 (es)
MX (1) MX2020002702A (es)
SG (1) SG11202001806TA (es)
WO (1) WO2019051541A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117220A1 (en) 2013-02-01 2014-08-07 Transbio Ltd Anti-cd83 antibodies and use thereof
WO2019165156A1 (en) 2018-02-23 2019-08-29 H. Lee Moffitt Cancer Center And Research Institute Inc. Cd83-binding chimeric antigen receptors
US20200108098A1 (en) * 2018-02-23 2020-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Anti-cd83 chimeric antigen receptor expressing t regulatory cells
AU2020334893A1 (en) * 2019-08-16 2022-02-24 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptors for treating myeloid malignancies
WO2021258140A1 (en) * 2020-06-23 2021-12-30 Kira Biotech Pty Limited Cd83 binding protein conjugates for treating lymphoma
US20230331841A1 (en) * 2022-03-23 2023-10-19 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117220A1 (en) * 2013-02-01 2014-08-07 Transbio Ltd Anti-cd83 antibodies and use thereof
AU2014364593A1 (en) * 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
EP3209695A4 (en) * 2014-10-23 2018-05-30 DendroCyte BioTech Pty Ltd Cd83 binding proteins and uses thereof
WO2016073380A1 (en) * 2014-11-03 2016-05-12 Genentech, Inc. Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment

Also Published As

Publication number Publication date
WO2019051541A1 (en) 2019-03-21
EP3681536A1 (en) 2020-07-22
US20200277396A1 (en) 2020-09-03
KR20200066613A (ko) 2020-06-10
EP3681536A4 (en) 2021-06-09
CN111565749A (zh) 2020-08-21
JP2020533384A (ja) 2020-11-19
CA3074379A1 (en) 2019-03-21
SG11202001806TA (en) 2020-03-30
AU2022204077A1 (en) 2022-06-30
AU2018333275A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
MX2020002702A (es) Metodo de tratamiento.
ZA202007246B (en) Humanized and affinity matured antibodies to fcrh5 and methods of use
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
ZA202101797B (en) Hair treatment compositions, methods, and kits for treating hair
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
MX2016009010A (es) Anticuerpos anti-gen de activacion de linfocitos (lag-3) para tratar neoplasias hematologicas.
AU2017225061B2 (en) Biomarkers and methods of treating PD-1 and PD-L1 related conditions
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
EP4663755A3 (en) Method
BR112021012631A2 (pt) Anticorpos anti-ctla4 e métodos de uso dos mesmos
MX2020002216A (es) Metodos y composiciones para detectar y tratar endometriosis.
MX2020006297A (es) Variantes de cd19.
MX357708B (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
WO2013090633A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
EP3538124A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA
EP4014262A4 (en) Method and system for color neutral transparent photovoltaics
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
WO2018097712A8 (en) PROCESS FOR PREPARING A GLUCIDIC AND / OR PROTEIN PRODUCT
EA201891478A1 (ru) Способы и композиции для оценки риска возникновения рака
EA202090565A1 (ru) Композиции и способы лечения диффузной в-крупноклеточной лимфомы
MX377276B (es) Profármacos de antagonista de (s)-1-fenil-2-(piridin-2-il) etanamina (nmda).
MX2018001493A (es) Gdf-15 como biomarcador de toxicidad hematologica.
EA201690446A1 (ru) Лечение множественной миеломы
WO2016110818A3 (en) Novel therapy